Esperion (ESPR) Reports Q4 Preliminary Results, Stock Down

By NASDAQ13 days ago

AD

Esperion Therapeutics ESPR announced preliminary sales numbers for fourth-quarter 2020. Notably, the company’s expectation for the quarter looks gloomy. Alongside, the company also provided guidance for operating expense in 2021 and announced an agreement with privately-held Se

Continue read on nasdaq.com